RECONCILIATION OF GAAP TO NON-GAAP FIGURES The following tables reconcile GAAP figures to the figures stated in the Letter to Shareholders and graphs in this annual report that are not prepared in conformity with GAAP. These non-GAAP figures are adjusted for the impact of foreign exchange, divestitures, the assumption of direct sales responsibility and the associated buy-back of inventory in the remaining countries where Baxter International Inc. was the Company’s distributor, the acquisition of the Japan business, and/or other non-recurring items. Management has determined that inclusion of these non-GAAP figures provides a more meaningful comparison of the Company’s operating results for the periods presented and better reflect the Company’s ongoing operations. For more information, see Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) and the notes to the consolidated financial statements (“Note”). Sales 2000-2002 (in millions) 2002 2001 2001 2000 2000 1999 Sales as reported (GAAP) $ 704.0 $ 692.1 $ 692.1 $ 803.8 $ 803.8 $ 905.0 Adjustment for perfusion services divestiture — (58.9) (58.9) (117.3) — — Adjustment for perfusion products divestiture — — — (29.4) (29.4) (52.1) Adjustment for Novacor divestiture — — — (2.5) (2.5) (5.0) Adjustment for Japan on a consolidated basis — 27.3 — — — — Adjustment for Japan on a equity basis — — — (28.9) (28.9) (95.9) Adjustment for assumption of direct sales (a) 3.8 — — — — — Adjustment for foreign exchange 3.5 4.2 5.3 (14.1) 23.4 4.9 Underlying sales (non-GAAP) $ 711.3 $ 664.7 $ 638.5 $ 611.6 $ 766.4 $ 756.9 Underlying sales growth (non-GAAP) 7.0% 4.4% 1.3% (a) Adjustment for the assumption of direct sales responsibility and the associated buy-back of inventory in the remaining countries where Baxter International Inc. was the Company’s distributor. S30 Edwards Lifesciences Corporation Sales by Region 2002 U.S. Europe Japan R.O.W. Reported sales by region as a percent of total sales (GAAP) 55% 22% 13% 10% Adjustment for Japan on a consolidated basis (6%) (2%) 9% (1%) Adjustment for foreign exchange (2%) 2% 0% 0% Adjusted sales by region as a percent of total sales (non-GAAP) 47% 22% 22% 9% Other Cardiac Critical Distributed Surgery Care Vascular Perfusion Products Reported sales by product line as a percent  of total sales (GAAP) 52% 33% 7% 6% 2% Adjustment for Japan on a consolidated basis (4%) (1%) 0% 2% 3% Adjusted sales by product line as a percent  of total sales (non-GAAP) 48% 32% 7% 8% 5% Sales by Product Line